Yunnan Walsun Biotech Co., Ltd. has seen its ESG rating upgraded to BBB by MSCI, a significant leap from its previous B rating and a reflection of the company’s industry-leading sustainability practices. This achievement underscores Walsun’s commitment to ESG management, aligning with global investment standards and strategies.
Walsun Biotech, known for its innovative vaccine development, has been recognized by six major domestic ESG rating agencies with A-level ratings or higher. The company’s dedication to ESG is evident in its comprehensive governance structure, which includes a sustainable development committee and a systematic ESG indicator system, enhancing risk management and value creation.
The company’s focus on innovation in vaccine development is evident, with a robust pipeline that includes meningitis, pneumonia, HPV, and mRNA COVID-19 vaccines. Walsun Biotech ranks sixth globally among vaccine manufacturers and has supplied over 330 million doses of its vaccines to the market.
Walsun Biotech’s expansion into overseas markets, particularly in developing countries, is supported by strategic collaborations and contributions to local vaccine production. The company’s social responsibility initiatives include significant financial donations and vaccine donations, supporting health and educational programs.
Committed to sustainable development, Walsun Biotech integrates green ecological practices and high environmental standards across its operations, contributing to the dual carbon goals and ecological civilization construction. The company’s technological advancements and upgraded production facilities have led to improved energy efficiency and reduced waste emissions.
Despite complex external challenges and industry competition, Walsun Biotech remains dedicated to its mission of ‘health for all,’ continuously advancing its sustainable development strategy and ESG integration across all aspects of its business. -Fineline Info & Tech
